Inhibitor in a Tunnel

The enzyme choline acetyltransferase (ChAT) catalyzes the synthesis of the neurotransmitter acetylcholine and could be a target molecule for pharmaceuticals. A Swedish research team has determined the mechanism by which arylvinylpyridinium (AVP), a known class of ChAT inhibitors, functions. ChAT manufactures the actual agent itself by attaching coenzyme A (CoA) to AVP.

The Enzyme Choline Acetyltransferase (ChAT)

Acetylcholine passes on nerve impulses in synapses, among other things. Changes in the amount or activity of ChAT, which produces acetylcholine from choline and acetylcoenzyme A (AcCoA), have been observed in a variety of diseases, such as Alzheimer’s disease, schizophrenia, congenital disruption of signal conduction between nerves and muscles, and chronic viral infections. In addition, inhibition of ChAT could serve as an effective treatment for poisoning by organophosphate neurotoxins.

To date, suitable ChAT inhibitors have been unavailable. Arylvinylpyridinium compounds (AVPs) were good inhibitors in vitro, but their pharmacological profile proved to be inconsistent. A team at the Swedish Defense Research Agency and Umeå University led by Fredrik Ekström has now been able to clarify the inhibition mechanism of AVPs and provide insights that could be used as the basis for developing ChAT inhibitors with better effectiveness and bioactivity.

New Method for the Development of Choline Acetyltransferase Inhibitors

The researchers were able to demonstrate that the actual bioactive agents are not the AVPs themselves, but the adduct they form with CoA. Connection of these two components is carried out by ChAT itself. The enzyme builds its own inhibitor starting from an exogenic precursor (AVP) and an endogenic co-substrate (CoA). The reaction is an unusual hydrothiolation, which forms a bond between the thiol group of the CoA and the vinyl group of the AVP.

The binding and catalytic domains in ChAT form a narrow “tunnel” that passes across the enzyme. X-ray crystallographic studies of human ChAT in the presence of CoA and AVP showed that the inhibiting adduct is embedded deep within this tunnel. Interactions with hydrophobic pockets near the choline binding site have significant effects on the strength of ChAT inhibitors.

The researchers hope that their discoveries will allow for the development of novel ChAT inhibitors with improved strength and duration of activity.